ACHIEVE LIFE SCIENCES INC (ACHV) competitors & alternatives
Health Care · NASDAQ
ACHIEVE LIFE SCIENCES INC (ACHV)'s top competitors and alternatives — its most similar public companies — include Pfizer (PFE), NOVARTIS AG (NVS), INHIBIKASE THERAPEUTICS INC (IKT), PRELUDE THERAPEUTICS INC (PRLD), ENLIVEN THERAPEUTICS INC (ELVN), ASSEMBLY BIOSCIENCES INC (ASMB), AVALO THERAPEUTICS INC (AVTX), RECURSION PHARMACEUTICALS INC CLAS (RXRX), KAILERA THERAPEUTICS INC (KLRA), COGENT BIOSCIENCES INC (COGT), Aldeyra Therapeutics, Inc. (ALDX) and ALTO NEUROSCIENCE INC (ANRO). These are ACHIEVE LIFE SCIENCES INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ACHV competitors & alternatives
-
PfizerPFEHealth Care
Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular,…
$24.82 (as of 2026-07-22) · market cap $142.0B
-
NOVARTIS AGNVS
Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
$153.08 (as of 2026-07-22) · market cap $229.2B
-
INHIBIKASE THERAPEUTICS INCIKTHealth Care
A pre-revenue biotech company developing IKT-001, a novel therapeutic targeting pulmonary arterial hypertension, currently in Phase 3 clinical trials with no…
$2.17 (as of 2026-07-22) · market cap $287M
-
PRELUDE THERAPEUTICS INCPRLDHealth Care
An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
$3.92 (as of 2026-07-22) · market cap $313M
-
ENLIVEN THERAPEUTICS INCELVNHealth Care
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing targeted small-molecule inhibitors, with a primary focus on its lead BCR-ABL…
$52.85 (as of 2026-07-22) · market cap $3.8B
-
ASSEMBLY BIOSCIENCES INCASMBHealth Care
Assembly Biosciences develops next-generation antivirals targeting herpes and hepatitis viruses, with a portfolio advancing through clinical trials and now…
$26.04 (as of 2026-07-22) · market cap $513M
-
AVALO THERAPEUTICS INCAVTXHealth Care
Clinical-stage biotech developing abdakibart, a humanized anti-IL-1β antibody for hidradenitis suppurativa with Phase 2 data readout expected mid-2026.
$18.15 (as of 2026-07-22) · market cap $961M
-
RECURSION PHARMACEUTICALS INC CLASRXRXHealth Care
Recursion is a clinical-stage TechBio company using an AI-native operating system and massive biological datasets to industrialize and accelerate the drug…
$2.98 (as of 2026-07-22) · market cap $1.6B
-
KAILERA THERAPEUTICS INCKLRAHealth Care
A clinical-stage biotech developing a diversified pipeline of GLP-1-based obesity management drugs, led by a dual GLP-1/GIP agonist injectable designed to…
$17.79 (as of 2026-07-22) · market cap $2.4B
-
COGENT BIOSCIENCES INCCOGTHealth Care
Cogent Biosciences is a clinical-stage biotechnology company developing precision protein kinase inhibitors, primarily targeting KIT mutations for the…
$39.54 (as of 2026-07-22) · market cap $6.8B
-
Aldeyra Therapeutics, Inc.ALDXHealth Care
Aldeyra is a clinical-stage biotech pursuing FDA approval of reproxalap, an aldehyde dehydrogenase activator for ophthalmologic inflammation, dependent on…
$1.70 (as of 2026-07-22) · market cap $106M
-
ALTO NEUROSCIENCE INCANROHealth Care
Alto Neuroscience is a clinical-stage biotech developing precision medicines for neuropsychiatric conditions by using biomarkers to match patients to targeted…
$27.23 (as of 2026-07-22) · market cap $1.0B
Not quite? Describe exactly what you want →
Peers are ACHIEVE LIFE SCIENCES INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ACHIEVE LIFE SCIENCES INC (ACHV).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.